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Abstract As the term “masked mycotoxins” encompasses
only conjugated mycotoxins generated by plants and no
other possible forms of mycotoxins and their modifica-
tions, we hereby propose for all these forms a systematic
definition consisting of four hierarchic levels. The highest
level differentiates the free and unmodified forms of my-
cotoxins from those being matrix-associated and from
those being modified in their chemical structure. The
following lower levels further differentiate, in particular,
“modified mycotoxins” into “biologically modified” and
“chemically modified” with all variations of metabolites
of the former and dividing the latter into “thermally
formed” and “non-thermally formed” ones. To harmonize
future scientific wording and subsequent legislation, we
suggest that the term “modified mycotoxins” should be
used in the future and the term “masked mycotoxins” to
be kept for the fraction of biologically modified myco-
toxins that were conjugated by plants.
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Background
The rationale behind the new definition presented here was an
ongoing discussion about the term “masked mycotoxins.” This
term has been introduced as early as 1990 by Gareis et al. to
describe a zearalenone glucoside: “Since zearalenone–glyco-
side is not detected during routine analysis, but hydrolysed
during digestion, it seems likely that such ‘maskedmycotoxins’
are involved in cases of mycotoxicoses.” Meanwhile, the term
“masked mycotoxins” is established internationally, but has
been used ambiguously. In 2011, the International Life
Science Institute (ILSI) has adopted the following definition:
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“Mycotoxin derivatives that are undetectable by conventional
analytical techniques because their structure has been changed
in the plant are designated masked mycotoxins”. According to
Berthiller et al. (2013), the term “masked mycotoxins” should
exclusively be used for plant metabolites of mycotoxins in
order to avoid misunderstandings and confusion.
However, there are other substances derived from myco-
toxins, which likewise are not detectable in routine analysis,
but which are primarily not produced by plants. Besides mam-
malian and fungal metabolites these include thermally formed
specimens arising in the course of processing. All these com-
pounds are not covered by the term “masked mycotoxins.”
Accordingly, there is a need for a systematical definition of
all potential mycotoxin derivatives (beyond the “parent com-
pound”). Therefore, the definition presented here should con-
tribute to the harmonization of terminology in scientific parlance
to enable progressing to further questions in the future. From the
perspective of consumer health protection, for example, the
identification ofmycotoxins with all modifications thereof caus-
ing toxic effects in humans and animals after primarily oral
ingestion is of enormous interest. Accordingly, also data on
the bioavailability, toxicology, and analysis of individual myco-
toxin derivatives will be discussed in the following.
Although it has been shown in the past few years that
glucosides of zearalenone (ZEN-14-Glc) and deoxynivalenol
(DON-3-Glc) possess toxic potential, the derivation of toxico-
logical reference values as well as the setting of maximum levels
in food and feed is based exclusively on the particular parent
compounds (in this case ZEN and DON). The only exceptions
so far are (1) the maximum levels of the metabolite aflatoxin M1
in milk (Commission Regulation (EC) no. 1881/2006) and (2) a
derivation by the Joint FAO/WHO Expert Committee on Food
Additives (JECFA) of a provisional maximum tolerable daily
intake (PMTDI) as well as an acute reference dose (ARfD) for
the group of DON and its two metabolites/precursors 3-acetyl-
DON and 15-acetyl-DON (see also chapter “Knowledge in
toxicology”). A consideration of other related mycotoxins, e.g.,
of DON-3-Glc, is currently being controversially discussed.
However, the literature data seem to be too limited at the
moment for a conclusive decision.
From the perspective of consumer health protection, risk
assessment should cover all mycotoxin compounds potential-
ly leading to toxic effects in humans and animals after oral
ingestion. In this sense, the exclusive focus on mycotoxin
compounds that are produced by plants is insufficient, al-
though Berthiller et al. (2013) argued with a lower toxicity
of the latter. However, this cannot be assumed to be a general
rule. Therefore, the exclusive use of the term “masked myco-
toxins” does not seem to appear adequate. However, since the
term “masked mycotoxins” has already been established, it
should be used as defined before and limited to plant metab-
olites of mycotoxins. Further reasons for this recommendation
are discussed in the following sections.
Drawbacks of the term “masked” mycotoxins
As detailed before, “masking” initially referred to analytical
issues and no underlying structures or origins were supposed.
Since then, the term “masked” has been used ambiguously
along with other terms such as “bound,” “hidden,” and “con-
jugated” until ILSI defined masked mycotoxins as plant me-
tabolites (Berthiller et al. 2013). In the latter review, masked
mycotoxins were further differentiated into extractable and
bound (non-extractable) mycotoxins and the latter group fur-
thermore into “covalently and non-covalently attached to
polymeric carbohydrate or protein matrices.” However, even
in the review by Berthiller et al. (2013), non-enzymatically
formed mycotoxin modifications such as patulin bound to
solids in cloudy apple juices have been termed “masked,”
which also underlines the need of a more concise and system-
atic definition.
Apart from its ambiguous use, there are several further
constraints of the term “masked mycotoxins.” In inorganic
analysis, for instance, masked is used in a different sense, i.e.,
as an intended analytical procedure to mask ions in
complexometry that usually interfere with the determination
of the target ion (Schwarzenbach and Flaschka 1965).
Moreover, as analytical methods rapidly evolve, some
compounds (in particular those for which reference substances
are available) nowadays might well be “detected during rou-
tine analysis” (Gareis et al. 1990) and no longer being masked
according to the original definition.
Another weakness of the term “masked” is that the under-
lying reaction occurring in plants is not intended to “hide” the
toxins but simply to detoxify them. Thus “masked” is an
anthropocentric term with a negative connotation, which is
not justified.
The most striking argument, however, is the missing inclu-
sion of other potentially relevant forms of mycotoxins such as
mammalian metabolites or thermally generated modifications.
New definition proposed
In order to encompass all possible forms in which mycotoxins
and their modifications can occur, we hereby propose a sys-
tematic definition consisting of four hierarchic levels
(Table 1), the highest of which differentiates the free and
unmodified forms of mycotoxins from those being matrix-
associated and from those being modified in their chemical
structure. The following lower levels further differentiate the
single specimens in more detail. For a better understanding,
Table 1 provides single examples for the different categories.
The emphasis of the definition has been placed on processes
for generation to include all known and conceivable com-
pounds related to mycotoxins. As some molecules can be
generated by different ways, the assignment cannot always
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be unequivocal, i.e., some compounds belong to more than
one category. The rationale behind this is to keep the defini-
tion open for yet unknown compounds.
Definition of the single categories and examples
Free
According to this definition the term “free” or “unmodified”
mycotoxins describes the basic mycotoxin structures formed
as toxic secondary metabolites by various fungi in well-
known biosynthetic pathways. Examples are ochratoxin A,
aflatoxin B1, fumonisin FB1, zearalenone, deoxynivalenol,
and also 3- and 15-acetyl-deoxynivalenol, which are also
formed during the biosynthetic pathway. But especially the
latter two substances, 3- and 15-acetyl-deoxynivalenol, may
be placed into more than one category. Recent developments
of transgenic plants with trichothecene-O-acetylase activity
for conjugation of DON may render 3-acetyl-DON also to
fall into the category conjugated by plants (masked)
(Karlovsky 2011).
Matrix-associated
This term should be used for mycotoxins, which (1) form
either complexes with matrix compounds or are physically
dissolved or trapped or (2) are covalently bound to matrix
components or a combination of both effects. Examples for
covalently bound forms of mycotoxins are fumonisins bound
to starch or proteins as was proposed and shown for the first
time by Shier et al. (2000) using radiolabelled fumonisin B1 in
model experiments although the exact structure was not clear
(Shier 2000). The covalent binding of fumonisins to starch
and proteins was later confirmed by Seefelder et al. (2003) in
model experiments using methyl α-D-glucopyranoside as
starch model and various amino acids as protein model.
Detailed MS and NMR studies showed that fumonisins are
able to bind to polysaccharides and proteins via their two
tricarballylic acid side chains (Seefelder et al. 2003).
Recently also the covalent binding of ochratoxin A (OTA) to
polysaccharides via the carboxylic acid group of OTA during
the roasting of coffee has been shown by Bittner et al. (2013).
Also, DON-oligosaccharides have been described recently
(Zachariasova et al. 2012).
Modified
The term “modified mycotoxins” describes any modification
of the basic chemical structure of mycotoxins either by chem-
ical or biological modifications.
Biologically modified
Biologically modified mycotoxins include on the third level
(see Table 1) any functionalization during phase 1-metabolism,
for example aflatoxin B1 exo-8,9-epoxide, which is the afla-
toxin metabolite that reacts covalently with DNA to form the
adducts responsible for the toxic effects.
Table 1 Systematic definition of “modified mycotoxins”
1st level 2nd level 3rd level 4th level Example
Free mycotoxins DON, Aflatoxin B1, 3-acetyl-
DON, 15-acetyl-DON
Matrix-associated
mycotoxins
Complexes, physically dissolved
or trapped
Covalently bound Fumonisines bound to starch,
OTA- and DON-
oligosaccharides
Modified mycotoxins Biologically modified Functionalised
(phase 1–metabolites)
Aflatoxin B1-epoxide
Conjugated (phase 2 –
metabolites)
Conjugated by plants
(= masked according
to ILSI)
DON-3-glucoside
Conjugated by animals DON-3/8/15-glucuronide,
HT2-3/4-glucuronide
Conjugated by fungi ZEN-14-sulfate
Differently modified Deepoxy-DON (=DOM-1)
Chemically modified Thermally formed norDON A-C, N-carboxy-
methyl-FB1, 14-(R)-OTA
Non-thermally formed DON-sulfonate, norDON A-C
(under alkaline conditions)
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Furthermore, mycotoxin conjugates such as phase 2-me-
tabolites are also defined as biologically modified. These
includes on the 4th level (1) conjugation reactions by plants
such as the formation of DON-3-Glc or ZEN-14-Glc, which
are defined as masked mycotoxins by ILSI (Berthiller et al.
2013); (2) conjugation reactions by animals such as the for-
mation of DON-3/8/15-glucuronides or HT2-3/4-glucuro-
nides, with the structures of new glucuronides recently having
been elucidated (Welsch and Humpf 2012; Uhlig et al. 2013);
and (3) conjugations by fungi as for example the formation of
ZEN-14-sulfate (Plasencia and Mirocha 1991) or the forma-
tion of N-acyl and O-acyl fumonisins by Fusarium
verticillioides (Bartók et al. 2013). All other biological mod-
ifications are summarized under the term “differently modi-
fied” (see Table 1) and include for example deepoxy-DON
(DOM-1) as an intestinal metabolite of DON, which is formed
by the microbiota of animals and humans (Eriksen et al. 2002;
Gratz et al. 2013).
Chemically modified
Chemically modified mycotoxins are currently the largest
group of modified mycotoxins and can be classified as “ther-
mally formed” and “non-thermally formed” on the third level
(see Table 1).
Thermal degradation reactions as well as thermal modifi-
cations occur during food and feed processing including bak-
ing, roasting, frying, or extruding. Thermal degradation prod-
ucts have been described for several mycotoxins. A prominent
example is fumonisin FB1 which can react in a Maillard-type
reaction with reducing sugars leading to N-(1-deoxy-D-
fructos-1-yl) fumonisin B1 and N-(carboxymethyl)fumonisin
B1 (for a review, see Humpf and Voss 2004). The latter one is
the stable end product and detectable in processed corn sam-
ples in concentrations up to 76 μg/kg (Seefelder et al. 2001).
Thermal degradation products of DON have been identi-
fied as norDON A-F and 9-hydroxymethyl DON lactone
(Bretz et al. 2006; Young et al. 1986) in model heating
experiments. However, some of these compounds are also
formed under alkaline conditions without thermal treatment.
The significance of these DON degradation products was
proven by analyzing commercially available food samples.
Only the three degradation products norDON A, B, and C
were detectable in 29–66 % of the samples with mean con-
centrations ranging from 3 to 15 μg/kg. Further examples of
thermal modifications of mycotoxins are norNIVA, norNIV
B, norNIV C, and NIV lactone as degradation products of
nivalenol of which only norNIV B was detectable in commer-
cially available samples (Bretz et al. 2005).
As degradation reactions of ochratoxin A during the
roasting of coffee, the isomerization to 14-(R)-ochratoxin A
and the decarboxylation to 14-decarboxy-ochratoxin A were
identified as main reactions. The analysis of 15 coffee samples
from the German market revealed that the ochratoxin A dia-
stereomer 14-(R)-ochratoxin Awas formed in amounts of up
to 25.6 % relative to ochratoxin A and the decarboxylation
product was only detectable in traces(Cramer et al. 2008).
Model experiments with T-2 toxin revealed three thermal
degradation products of which only one was detectable in
traces in commercial food samples (Beyer et al. 2009).
Examples for non-thermal modifications of mycotoxins are
the formation of hydrolyzed fumonisins (HFBx) or the above
mentioned norDON A–C degradation products formed under
alkaline conditions (Humpf and Voss 2004; Young et al.
1986). Other examples are degradation reactions induced by
UV light as was recently shown for ochratoxin A and citrinin
(Schmidt-Heydt et al. 2012) or DON sulfonate generated by
treatment of contaminated feed with sodium bisulfite (Beyer
et al. 2010).
At this point, we would like to emphasize once more that
some compounds fall in different categories. For example,
hydrolyzed fumonisins (HFBx), on the one hand, are biolog-
ically modified and are formed by the intestinal microbiota
(Fodor et al. 2008) and, on the other hand, are formed under
alkaline conditions during food processing (Humpf and Voss
2004).
Analytical considerations
In order to collect occurrence data and to assess the effects of
consumption of mycotoxins on the health of animals and
humans, a reliable analytical detection not only of free but
also of modified and matrix-associated mycotoxins is inevita-
ble. For the determination of free mycotoxins in food and
feed, a huge variety of analytical methods has already been
developed and mainly based either on chromatographic
methods such as thin layer chromatography, gas chromatog-
raphy, or liquid chromatography (also coupled to mass spec-
trometry) or on immunochemical methods such as enzyme-
linked immunosorbent assays (ELISA). In contrast to chro-
matographic methods, immunochemical methods sometimes
respond to more than one compound (i.e., the free mycotoxin
and its modification) depending on the antibody used for
analysis and resulting in an undistinguishable signal for more
than one compound (Goryacheva et al. 2009; Goryacheva and
De Saeger 2012). This effect is known as “cross-reactivity”
and was shown for example for DON and DON-3-Glc
(Ruprich and Ostry 2008). In this case, cross-reactivity varies
depending on the antibody between 8 and 157% (Tangni et al.
2010). Another example is the thermal isomerization product
14-(R)-ochratoxin A, which is only binding to immunoaffinity
columns of one supplier, although only one stereocenter is
different compared to OTA (Cramer et al. 2008).
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In general, there are three different approaches for the
analysis of modified mycotoxins: direct and indirect determi-
nation as well as not-targeted analysis.
Direct analysis offers the advantage that conventional,
standardized analytical methods are suitable, but these need
to be adjusted and optimized according to the structurally
related chemical properties (polarity, altered extraction behav-
ior, detection characteristics, etc.) compared to the free myco-
toxins. The huge disadvantage of direct analysis is the fact that
up to now only a few modified mycotoxins (e.g., DON-3-Glc)
are available as reference substances for analysis.
This problem can be circumvented by indirect determina-
tion, where the modified forms are transformed into the native
mycotoxin, which then can be analyzed by “routine analysis.”
Therefore, chemical and enzymatic hydrolysis (e.g., for con-
jugates or bound compounds), reduction (e.g., for biotransfor-
mation products of the phase I reaction) and other specific
reactions are used during sample preparation. However, indi-
rect analysis of modified mycotoxins provides only limited
information about the structure and amount of the mycotoxin
specimens originally present in the sample. Thus, a distin-
guished estimation of the deduced toxicological effects in
humans or animals after consumption of food/feed contami-
nated with native and modified mycotoxins are hardly
possible.
So, it can be concluded that in the last years, more andmore
direct methods based on LC-MS have been developed and up
to now, have become the methods of choice for the determi-
nation of modified mycotoxins (Berthiller et al. 2007; Li et al.
2013). More detailed information on the analysis of modified
mycotoxins can be found in recent publications (Dall’Asta
et al. 2010; DiMavungu and De Saeger 2011; De Boevre et al.
2012; Berthiller et al. 2013).
However, it is not only possible to identify and quantify
known substances, the so-called target mycotoxins. Also,
previously unknown derivatives of mycotoxins can be detect-
ed by so-called non-targeted analysis using, for example,
high-resolution mass spectrometry (HR-MS) coupled with
liquid chromatography like UPLC (Cirlini et al. 2012). In this
way, Nakagawa et al. (2013) identified new modified myco-
toxins (mycotoxin glucosides) derived from type A trichothe-
cenes in commercially available corn powder reference mate-
rial. These new glucosides (neosolaniol–glucoside and
diacetoxyscirpenol–glucoside) were identified based on accu-
rate mass measurements of characteristic ions and fragmenta-
tion patterns using a high-resolution liquid chromatography–
Orbitrap mass spectrometric analysis (Nakagawa et al. 2013).
A review of MS approaches to study phase II metabolites in
general has been published (Levsen et al. 2005).
Overall, all analytical methods serve the purpose to obtain
differentiated data of free and modified mycotoxins in
food/feed, to elucidate the occurrence and exposition with
these compounds.
Occurrence
Long before the term “masked mycotoxins” emerged, modi-
fied mycotoxins have been discovered. For example, aflatoxin
M1 as a metabolite of aflatoxin B1 excreted with milk has been
reported almost 50 years ago (Masri et al. 1967).
In the last years, increasing quantitative data of modified
mycotoxins have been published, in particular in the field of
Fusarium toxins. This is obviously due to emerging aware-
ness and the predominance of LC-MS/MS equipment in lab-
oratories dealing with mycotoxins.
Among all modified mycotoxins, most occurrence data
exist for DON-3-Glc, which was detected in naturally con-
taminated maize and wheat for the first time in 2005
(Berthiller et al. 2005). Subsequent surveys indicated spora-
dically high contaminations of DON-3-Glc exceeding
1,000 μg/kg in naturally contaminated wheat (Berthiller
et al. 2009). Molar ratios of DON-3-Glc in relation to unmod-
ified DON were found to be highly variable in the range
between 20 and over 70 % depending on cereal species and
genotype, country and year of harvest (Berthiller et al. 2009;
Desmarchelier and Seefelder 2011; De Boevre et al. 2012).
Apart from wheat and maize, DON-3-Glc also has been
detected in oats (De Boevre et al. 2012) and barley (Lancova
et al. 2008) thus being transferred into beer made of the latter
(Kostelanska et al. 2009). Cereal contamination with DON-3-
Glc was reported to occur worldwide according to surveys
from the UK (Vendl et al. 2010), the Czech Republic
(Malachova et al. 2011), China (Li et al. 2012), and Canada
(Tran et al. 2011). For occurrence of further modified myco-
toxins, e.g., conjugates of ZEA (De Boevre et al. 2012 and
2013; Berthiller et al. 2009) or of T-2 and HT-2 toxins
(Veprikova et al. 2012) or modified fumonisins (Humpf and
Voss 2004; Falavigna et al. 2012), some market reviews have
been published, but the reported data are still rather limited.
Knowledge in toxicology
Potential exposure to modified mycotoxins due to their pres-
ence in food and feed raises concern that modifiedmycotoxins
may pose an additional risk to human and animal health.
While conjugated and matrix-associated mycotoxins may be
cleaved by the gut microflora (e.g., DON-3-Glc→DON, Nagl
et al. 2012) or endogenous digestive enzymes (e.g.,
fumonisins bound to starch→fumonisins, Humpf and Voss
2004) to the parent compound and thus add to the systemic
exposure and toxicity of the free mycotoxin, other modified
mycotoxins may be less, equally or even more toxic than their
parent compound. To understand the toxicological relevance
and contribution of modified mycotoxins to the overall health
risk resulting from dietary intake of mycotoxins, it is thus
critical to assess the bioavailability and toxic potential of
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modified mycotoxins. In particular, while available in vitro
studies mostly suggest lower cytotoxic potential of modified
mycotoxins compared to their parent compound as exempli-
fied by DON derivatives in Table 2, few in vivo data on the
absorption, distribution, metabolism, and excretion (ADME)
and toxicity of modified mycotoxins are yet available.
The best studied examples so far involve derivatives of the
Fusarium mycotoxins DON and ZEN, e.g., DON-3-Glc, the
acetyl derivatives 3-acetyl-deoxynivalenol (3-Ac-DON), and
15-acetyl-deoxynivalenol (15-Ac-DON), and ZEN-14-Glc.
In vitro studies on the comparative toxicity of DON and its
acetylated derivatives demonstrate that 15-Ac-DON and 3-
Ac-DON are equally or less toxic compared to DON
(Table 2). In contrast to this and even more important, studies
on the acute oral toxicity of acetylated DON derivatives in
mice revealed similar LD50 values for DON and its 3-acetyl
and 15-acetyl metabolites, demonstrating that the oral toxic-
ities of 3-Ac-DON and 15-Ac-DON in vivo are comparable to
that of DON (Forsell et al. 1987; Yoshizawa and Morooka
1974). In evaluating the risk resulting from DON exposure,
Table 2 Cytotoxicity of modified DON derivatives compared to DON in different cell culture systems in vitro
Level of hierarchy Modified DON Cell culture system Assay IC50 (μM) Reference
Modified DON DON
1st Level: free mycotoxins 15-acetyl-DON 3T3 cells BrdU 1.5 1.5 Eriksen et al. 2004
Bovine PBMC MTT 0.5 0.5 Dänicke et al. 2011
3-acetyl-DON 3T3 cells BrdU 14.5 1.5 Eriksen et al. 2004
Bovine PBMC MTT 2.6 0.5 Dänicke et al. 2011
1st Level: modified mycotoxins
2nd Level: biologically modified
3rd Level: conjugated (phase II metabolites)
4th Level: conjugated by plants
DON-3-O-glucoside WG-T/T LA (>20)b 0.8a Poppenberger et al. 2003
4th Level: conjugated by animals
DON-3-glucuronide K562 MTS (>270)b 1.31 Wu et al. 2007
3rd Level: differently modified
DOM-1 3T3 cells BrdU 83.1 1.5 Eriksen et al. 2004
Bovine PBMC MTT (>18)b 0.5 Dänicke et al. 2011
Porcine PBMC MTT (>23)b 1.18 Dänicke et al. 2010
IPEC-1 MTT (>23)b 1.33 Dänicke et al. 2010
IPEC-J2 MTT (>23)b 2.97 Dänicke et al. 2010
2nd Level: chemically modified
3rd Level: thermally formed
nor-DON-A IHKE WST-8 (>100)b 1.1 Bretz et al. 2006
3rd Level: non-thermally formed
DON-sulfonate Porcine PBMC MTT (>17)b 1.18 Dänicke et al. 2010
IPEC-1 MTT (>17)b 1.33 Dänicke et al. 2010
IPEC-J2 MTT (>17)b 2.97 Dänicke et al. 2010
HepG2 MTT (>100)b 41.0 Beyer 2009
Caco-2 MTT 9.2 2.0 Beyer 2009
IHKE MTT 8.1 1.6 Beyer 2009
3T3 cells Swiss mouse fibroblasts; BrdU 5-bromo-2-deoxyuridine, DNA synthesis; Caco-2 a human epithelial colorectal adenocarcinoma cell line;
HepG2 a human hepatoma cell line; IHKE an immortalized human kidney epithelial cell line; IPEC-1 and IPEC-J2 non-transformed Intestinal Porcine
Epithelial Cell lines; K562 erythroleukemia cell line; MTS methylthiazol tetrazolium, cell viability; MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide), cell viability; PBMC primary peripheral blood mononuclear cells; WG-T/T wheat germ extract-based coupled transcription/
translation system; WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt], cell viability
a Linearly interpolated from published data
b No IC50 derivable, highest tested concentrations are given in brackets
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the Joint FAO/WHO Expert Committee on Food Additives
(JECFA) considered the acetylated DON derivatives to con-
tribute to the total DON-induced toxicity and established a
group PMTDI and group ARfD for DON and its acetylated
derivatives (JECFA 2011). Similar to Ac-DONs, DON-3-
Glc may, at least in part, be hydrolyzed to DON in the
gastrointestinal tract and thus may contribute to the total
dietary exposure to DON. Following oral administration of
DON-3-Glc to rats, DON and its metabolites deoxynivalenol-
glucuronide (DON-3-GlcA) and deepoxy deoxynivalenol
(DOM-1) were recently identified as urinary metabolites of
DON-3-Glc (Nagl et al. 2012). Studies on the hydrolytic fate
of DON-3-Glc during digestion indicate that DON-3-Glc may
be cleaved by intestinal bacteria and thus become bioavailable
as DON (Berthiller et al. 2011). Therefore, it may be conclud-
ed that data on the toxic potential of DON-3-Glc using cellular
or molecular endpoints in vitro such as inhibition of protein
synthesis (Poppenberger et al. 2003) may not be accurate
predictors of systemic toxicity of DON-3-Glc in whole ani-
mals or humans.
DOM-1 is another example for cytotoxic assays being
insufficient to evaluate the overall toxicological relevance.
Although DOM-1 seems to be generally low toxic both for
bovine and porcine peripheral blood mononuclear cells
(PBMC) (Table 2) the interspecies differences in pre-
absorptive modification capability need to be considered in
evaluating the overall toxicity of DON for cattle and pigs.
While DON is nearly completely modified to DOM-1 in cattle
by rumen micro-organisms prior systemic absorption this
modification occurs also in the hindgut of pigs, but only very
small amounts of non-absorbed free DON reach this intestinal
segment. Therefore, in DON-exposed cattle, mostly DOM-1
is detectable in blood while in pigs the majority is in the form
of free DON (e.g., Dänicke and Brezina 2013).
Similarly to DON-3-Glc, glycosylation of the estrogenic
mycotoxin ZEN by plant UDP-glucosyltransferases to its
derivative ZEN-14-Glc has been shown to prevent binding
to estrogen receptors. While conjugation may present a means
of detoxification to protect the plant (Poppenberger et al.
2006), it is important for human and animal health risk as-
sessment to consider that ZEN-14-Glc may be cleaved during
digestion and release its active parent compound as demon-
strated in pigs (Gareis et al. 1990).
These examples emphasize the need for toxicokinetic and
toxicity data on modified mycotoxins to allow human and
animal health risk assessment. They also highlight some of the
issues that need to be considered:
& The systemic and local toxicological effects of modi-
fied mycotoxins depend on their release from the
matrix, metabolic modification within the digestive
tract, absorption, biotransformation, and finally, the
toxicodynamic potencies of modified mycotoxins and
their metabolites. Co-exposure to free and modified
mycotoxins needs to be considered in evaluating the
overall health risks
& Assessment of the comparative toxicity of modified my-
cotoxins in isolated cells may be a poor predictor of
toxicity in vivo as it rarely considers metabolic conversion
to the active metabolite
& Besides systemic toxicity, potential local effects of modi-
fied mycotoxins (or their metabolites) on the gastrointes-
tinal tract need to be considered
& Significant species differences and intra-species variation
in the composition and activity of the gut microflora and
thus metabolic conversion and bioavailability of toxico-
logically active metabolites may lead to significant inter-
and intra-species differences in the toxicity of modified
mycotoxins
Implications for legislation
The need for regulating modified mycotoxins has been
recognized by European regulatory bodies, but due to the
lack of toxicological data, implementation remained
vague until now. More specifically, the European
Commission (EC) asked the European Food Safety
Authority (EFSA) in July 2013 for a scientific opinion
on the risks for animal and public health related to the
presence of DON, metabolites of DON, and masked DON
in food and feed (M-2013-0260). EFSA accepted the
mandate (EFSA-Q-2013-00721) and an opinion is expect-
ed in the near future (www.efsa.europa.eu). As mentioned
before, only the acetylated derivatives of DON have been
added to DON for a PMTDI and an ARfD of the DON
group for sample-specific risk assessments (JECFA 2011).
Furthermore, EFSA received a request from EC for a
scientific opinion on the risks for animal and public
health related to the presence of metabolites and masked
or bound forms of certain mycotoxins in food and feed
(EFSA-Q-2013-00720).
Moreover, the European Commission pointed to the need
to “analyse also the masked mycotoxins in particular the
mono- and di-glycosylated conjugates of T-2 and HT-2 toxin”
in the current recommendation on indicative levels for the sum
of T-2 and HT-2 toxins in cereals and cereal-based foods
(European Commission 2013).
For all reasons mentioned before and in particular to
harmonize future scientific wording and subsequent leg-
islation, we suggest that the term “modified mycotoxins”
should be used in future. As the term “masked myco-
toxins” has been already introduced for plant metabolites,
we propose this term to be kept for the fraction of
Mycotoxin Res (2014) 30:197–205 203
biologically modified mycotoxins, conjugated by plants
(Table 1).
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